Advanced Biomed Inc. — Form 10-K
Filed October 13, 2026 · analyzed by the Periodic Agent
10-K
— Neutral
significance 8/100
What the filing says
Filing discloses Advanced Biomed Inc.'s authorized 400M shares of common stock ($0.001 par), standard voting and dividend rights, transfer agent (Transhare Corporation), and standard indemnification provisions. Officers Xiaomin Chen (CEO) and Mingze Yin (CFO) certify compliance with Sections 302 and 906 of Sarbanes-Oxley for fiscal year ended June 30, 2026. One subsidiary identified: Acellent Technologies (Hong Kong) Co. Limited. No material changes, transactions, or new business developments disclosed.
Why this rating
Routine periodic governance and structural disclosure; no new material events, transactions, or changes affecting the $2.7M company.
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.